Skip to main content

Advertisement

SpringerLink
Log in

TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Iron chelation therapy is an effective approach to the treatment of iron overload conditions, in which iron builds up to toxic levels in the body and may cause organ damage. Treatments using deferoxamine, deferasirox and deferiprone have been introduced and despite their disadvantages, they remain the first-line therapeutics in iron chelation therapy. Our study aimed to compare the effectiveness of the iron chelation agent TLc-A, a nano chelator synthetized based on the novel nanochelating technology, with deferoxamine. We found that TLc-A reduced iron overload in Caco2 cell line more efficiently than deferoxamine. In rats with iron overload, very low concentrations of TLc-A lowered serum iron level after only three injections of the nanochelator, while deferoxamine was unable to reduce iron level after the same number of injections. Compared with deferoxamine, TLc-A significantly increased urinary iron excretion and reduced hepatic iron content. The toxicity study showed that the intraperitoneal median lethal dose for TLc-A was at least two times higher than that for deferoxamine. In conclusion, our in vitro and in vivo studies indicate that the novel nano chelator compound, TLc-A, offers superior performance in iron reduction than the commercially available and widely used deferoxamine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008;10:997–1030.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Jacobs A. Low molecular weight intracellular iron transport compounds. Blood. 1977;50:433–9.

    CAS  PubMed  Google Scholar 

  3. Breuer W, Greenberg E, Cabantchik ZI. Newly delivered transferrin iron and oxidative cell injury. FEBS Lett. 1997;403:213–9.

    Article  CAS  PubMed  Google Scholar 

  4. Marsella M, Borgna-Pignatti C. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. Hematol/Oncol Clin N Am. 2014;28:703–27.

    Article  Google Scholar 

  5. Mair SM, Weiss G. New pharmacological concepts for the treatment of iron overload disorders. Curr Med Chem. 2009;16:576–90.

    Article  CAS  PubMed  Google Scholar 

  6. Danjou F, Origa R, Anni F, Saba L, Cossa S, Podda G, et al. Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment. Blood Cells Mol Dis. 2013;51:142–5.

    Article  CAS  PubMed  Google Scholar 

  7. Angelucci E, Baronciani D, Lucarelli G, Baldassarri M, Galimberti M, Giardini C, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol. 1995;89:757–61.

    Article  CAS  PubMed  Google Scholar 

  8. Aessopos A, Berdoukas V, Tsironi M. The heart in transfusion dependent homozygous thalassaemia today–prediction, prevention and management. Eur J Haematol. 2008;80:93–106.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Ceci A, Felisi M, De Sanctis V, De Mattia D. Pharmacotherapy of iron overload in thalassaemic patients. Expert Opin Pharmacother. 2003;4:1763–74.

    Article  CAS  PubMed  Google Scholar 

  10. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci. 1964;119:758–68.

    Article  CAS  PubMed  Google Scholar 

  11. Zanninelli G, Glickstein H, Breuer W, Milgram P, Brissot P, Hider RC, et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol. 1997;51:842–52.

    CAS  PubMed  Google Scholar 

  12. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574–8.

    Article  CAS  PubMed  Google Scholar 

  13. Baath JS, Lam WC, Kirby M, Chun A. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. Retina. 2008;28:894–9.

    Article  PubMed  Google Scholar 

  14. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360:516–20.

    Article  CAS  PubMed  Google Scholar 

  15. Otto-Duessel M, Brewer C, Gonzalez I, Nick H, Wood JC. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol. 2008;120:123–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583–7.

    Article  CAS  PubMed  Google Scholar 

  17. Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood. 2007;109:5157–9.

    Article  CAS  PubMed  Google Scholar 

  18. Hershko C, Link G, Konijn AM, Cabantchik ZI. Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci. 2005;1054:124–35.

    Article  CAS  PubMed  Google Scholar 

  19. Aslam N, Mettu P, Marsano-Obando LS, Martin A. Deferasirox induced liver injury in haemochromatosis. J Coll Physicians Surg-Pak: JCPSP. 2010;20:551–3.

    PubMed  Google Scholar 

  20. Imran FS, Phatak P. Deferasirox induced liver injury in haemochromatosis. J Coll Physicians Surg-Pak: JCPSP. 2011;21:718 (author reply).

    PubMed  Google Scholar 

  21. Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf. 2010;9:633–41.

    Article  CAS  PubMed  Google Scholar 

  22. Peters R. The nanopore connection to cell membrane unitary permeability. Traffic. 2005;6:199–204.

    Article  CAS  PubMed  Google Scholar 

  23. Boyapalle S, Mohapatra S, Mohapatra S. Nanotechnology applications to HIV vaccines and microbicides. J Glob Infect Dis. 2012;4:62–8.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Controll Release: Off J Controll Release Soc. 2008;132:164–70.

    Article  CAS  Google Scholar 

  25. Fakharzadeh S, Kalanaky S, Hafizi M, Goya MM, Masoumi Z, Namaki S, et al. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine. Vaccine. 2013;31:2591–7.

    Article  CAS  PubMed  Google Scholar 

  26. Fakharzadeh S, Sahraian MA, Hafizi M, Kalanaky S, Masoumi Z, Mahdavi M, et al. The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice. Int J Nanomed. 2014;9:3841–53.

    CAS  Google Scholar 

  27. Maghsoudi A, Fakharzadeh S, Hafizi M, Abbasi M, Kohram F, Sardab S, et al. Neuroprotective effects of three different sizes nanochelating based nano complexes in MPP(+) induced neurotoxicity. Apoptosis Int J Program Cell Death. 2015;20:298–309.

    Article  CAS  Google Scholar 

  28. Nazaran MH. Chelate compounds. Google Patents US8288587; 2012.

  29. Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, et al. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients. Hemoglobin. 2011;35:206–16.

    Article  CAS  PubMed  Google Scholar 

  30. Spraul CW, Schicketanz C. Lang GE [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis]. Klin Monatsbl Augenheilkd. 1996;209:31–6.

    Article  CAS  PubMed  Google Scholar 

  31. Porter JB, Taher AT, Cappellini MD, Vichinsky EP. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin. 2008;32:601–7.

    Article  CAS  PubMed  Google Scholar 

  32. Kontoghiorghes GJ. Hemoglobin. 2008;32(1–2):1–15.

    Article  CAS  PubMed  Google Scholar 

  33. Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25:725–42.

    Article  CAS  PubMed  Google Scholar 

  34. Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E. Recent developments in iron chelation therapy. Klin Padiatr. 2007;219:158–65.

    Article  CAS  PubMed  Google Scholar 

  35. Liu G, Men P, Perry G, Smith MA. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol. 2010;610:123–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Bonda DJ, Liu G, Men P, Perry G, Smith MA, Zhu X. Nanoparticle delivery of transition-metal chelators to the brain: oxidative stress will never see it coming! CNS Neurol Disord: Drug Targets. 2012;11:81–5.

    Article  CAS  Google Scholar 

  37. Liu G, Men P, Perry G, Smith MA. Chapter 5—Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Prog Brain Res. 2009;180:97–108.

    Article  CAS  PubMed  Google Scholar 

  38. Seshadri R, Colebatch JH, Fisher R. Urinary iron excretion in thalassaemia after desferrioxamine administration. Arch Dis Child. 1974;49:195–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012;26(Suppl 1):S16–9.

    Article  CAS  PubMed  Google Scholar 

  40. Papastamataki M, Delaporta P, Premetis E, Kattamis A, Ladis V, Papassotiriou I. Evaluation of liver fibrosis in patients with thalassemia: the important role of hyaluronic acid. Blood Cells Mol Dis. 2010;45:215–8.

    Article  CAS  PubMed  Google Scholar 

  41. Hodges YK, Weinberger HD, Stephens J, Horwitz MA, Horwitz LD. Desferri-exochelin, a lipid-soluble, hexadentate iron chelator, effectively removes tissue iron. Transl Res: J Lab Clin Med. 2006;148:63–71.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

All financial support was provided by the Department of Research and Development at the Sodour Ahrar Shargh Company. We are grateful to Etrat S Moghimi and Fakhrosadat Nasiri for their help in this project.

Author information

Authors and Affiliations

  1. Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran

    Somayeh Kalanaky, Maryam Hafizi, Sepideh Safari, Saideh Fakharzadeh & Mohammad Hassan Nazaran

  2. Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Maryam Hafizi

  3. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran

    Kazem Mousavizadeh

  4. Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran

    Mahboubeh Kabiri

  5. Department of Laboratory Science, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran

    Alireza Farsinejad

Authors
  1. Somayeh Kalanaky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maryam Hafizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sepideh Safari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazem Mousavizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mahboubeh Kabiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alireza Farsinejad
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Saideh Fakharzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mohammad Hassan Nazaran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Saideh Fakharzadeh or Mohammad Hassan Nazaran.

Ethics declarations

Conflict of interest

The other authors report no conflicts of interest in this work.

Additional information

M. H. Nazaran is the owner of Nanochelating technology and executive manager and chairman of the management board of Sodour Ahrar Shargh Company.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalanaky, S., Hafizi, M., Safari, S. et al. TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo. Int J Hematol 103, 274–282 (2016). https://doi.org/10.1007/s12185-015-1932-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-015-1932-8

Keywords

Search

Navigation